Skip navigation

Prescription drug use in U.S. fell last year

Prescription drug use in the U.S. fell last year, although total spending on drugs increased as prices rose sharply on brand-name products. Full story

FDA backs Vytorin after finishing study review

The Food and Drug Administration says patients should not stop taking Vytorin or other cholesterol-lowering drugs, based on its review of a controversial study. Full story

U.S. probes possible Vytorin link to cancer

U.S. government drug safety regulators said Thursday they are investigating whether the cholesterol-lowering drug Vytorin can increase patients' risk of developing cancer. Full story

FDA rejections may mean higher bar for drugs

Regulators ended last week and started this one by rejecting two potential blockbuster cholesterol drugs, leaving Wall Street wondering if tougher approval standards are here. Full story

Merck’s quarterly profit almost doubles

The drugmaker Merck & Co. says its profit almost doubled in the first quarter due to a $1.4 billion distribution from a partner drug company. It sales were slightly higher. Full story

Vytorin study confuses patients, divides doctors

Controversy has followed a study this week that showed that the expensive combination drug Vytorin was no more effective than one of its cheaper components used alone. Full story

Sponsored Links


Cholesterol combo not superior to solo drug

advertisement | ad info